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There is general agreement that loss of genetic material on chro-
mosome 9 is the most frequent genetic alteration in transitional
cell carcinoma of the urinary bladder (TCC). Chromosome arms
9p and 9q, often both, are lost entirely or in part (reviewed by
Ørntoft and Wolf, 1998; Knowles, 1999). Consistent loss of a
specific genomic region in tumour cells is usually considered as
evidence for the presence of a tumour suppressor gene. Accord-
ingly, available evidence indicates that loss on 9p targets the
CDKN2A locus. First, in most TCC with loss of heterozygosity
(LOH) on chromosome 9p, defects are detected in the remaining
allele of CDKN2A, involving deletion, promoter hypermethyla-
tion, or, less frequently, point mutation (Kai et al, 1995; Orlow
et al, 1995; Packenham et al, 1995; Williamson et al, 1995; Akao
et al, 1997; Gonzalgo et al, 1998; Florl et al, 2000). Second, the gene
encodes two distinct proteins involved in two separate, important
pathways regulating cell proliferation and genomic stability (Quelle
et al, 1995). Third, re-expression of one of the protein products,
p16INK4A, has been shown to cause cell cycle arrest in bladder
carcinoma cells (Grim et al, 1997; Bender et al, 1998). 
The issue regarding chromosome 9q is less clear-cut. The identi-
fication of tumour suppressor genes on 9q has been hampered by the
fact that in many TCC LOH has been observed across the entire
chromosome arm. Data accumulated from several laboratories on
the rarer partial deletions suggests at least three rather large target
regions (Habuchi et al, 1995; Hornigold et al 1999; Simoneau
et al, 1996; Habuchi et al, 1997; Nishiyama et al, 1999; Ohgaki
et al, 1999; van Tilborg et al, 1999; Simoneau et al, 2000; van
Tilborg et al, 2000). Several genes located on chromosome 9q are
good candidates from a functional point of view, e.g., PTCH or
TGFBRI. For these, inactivation of the remaining allele by dele-
tion, mutation, or hypermethylation at a significant frequency
could not be found (Simoneau et al, 1996; McGarvey et al, 1998,
1999; Tokunaga et al, 1999). Instead, second events – with modest
frequency – have been shown to inactivate the TSC1 and DBCCRI
genes whose functions in the urothelium are not understood
(Habuchi et al, 1998; Hornigold et al, 1999; Nishiyama et al,
1999). 
One alternative hypothesis accounting for the frequent loss of
9q in TCC is that it simply accompanies loss of 9p which is the
event selected for. In support of this idea, loss of the entire chro-
mosome is more frequent than that of 9q alone, and CDKN2A is
firmly established as a potent tumour suppressor locus. However,
as several reports describe more frequent loss of 9q in low grade
superficial papillary TCC (Zhao et al, 1999; Chow et al, 2000),
loss of 9q might be important for the development of papillary
tumours. Loss of 9p, including homozygous deletion of CDKN2, is
found at high frequency in muscle-invasive tumours as well. Since
many of these do not develop from papillary precursors, it is
possible that 9q LOH represents a passenger event accompanying
9p loss in these cases. 
Another relevant consideration arises from the recognition that
genomic alterations in tumours do not solely reflect selection for
functional alterations, but also the underlying mechanisms of
genetic instability. This notion has emerged, among others, from
the study of HNPCC, in which certain types of mutation, e.g.,
microsatellite instability, are favoured as a consequence of the
underlying defects in mismatch repair. Of many mutations occur-
ring, only a few are functionally selected for. In contrast, some
cases of colon cancer do not display microsatellite instability, but
Destabilization of chromosome 9 in transitional cell
carcinoma of the urinary bladder 
F Kimura1, AR Florl1, H-H Seifert1, J Louhelainen3, S Maas1, MA Knowles3 and WA Schulz1,2
1Urologische Klinik; and 2Center for Biological and Medical Research, Heinrich-Heine Universität, Moorenstrasse 5, D-40225 Düsseldorf, Germany; and 
3ICRF Cancer Medicine Research Unit, St James’s University Hospital, Leeds, UK 
Summary The most frequent genetic alteration in transitional cell carcinoma of the urinary bladder (TCC) is loss of chromosome 9 which
targets CDKN2A on 9p. The targets on 9q are not confirmed. Here, 81 advanced TCC specimens were investigated for loss of heterozygosity
(LOH) and homozygous deletions (HD) on chromosome 9q using multiplex analysis of microsatellite markers. 41/81 tumours (51%) showed
LOH on 9q, with LOH at all markers in 33 cases. Eight partial losses involved three regions in 9q12, 9q22.3, and 9q33– 9q34. No mutations
were identified in the candidate tumour suppressor gene DBCCR1 in three tumours showing restricted LOH at 9q32-33. 22% of the
specimens had HD at CDKN2A, but no HD was found on 9q. Two tumours had lost 9p only and five 9q only. 9q LOH was not related to tumour
grade or stage and present or absent with equal frequency in recurrent TCC. LOH on 9q correlated with the extent of genome-wide
hypomethylation (P < 0.0001) which extended into satellite sequences located in 9q12 juxtacentromeric heterochromatin. While the high
frequency of chromosome 9q loss in TCC may reflect destabilization of the chromosome related to hypomethylation of repetitive DNA, the
data are compatible with the existence of tumour suppressor genes on this chromosome arm. © 2001 Cancer Research Campaign
http://www.bjcancer.com 
Keywords: bladder cancer; chromosome instability; DNA methylation; LINE-1; tumour suppressor genes 
1887
Received 30 April 2001 
Revised 29 August 2001 
Accepted 19 September 2001 
Correspondence to: WA Schulz 
British Journal of Cancer (2001) 85(12), 1887–1893
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2154, available online at http://www.idealibrary.com on  http://www.bjcancer.comchromosomal loss and rearrangements, indicating widespread
chromosome instability (see Lindblom, 2001 for a recent review). 
Conceivably, chromosome instability might not affect all chro-
mosomes alike. For instance, DNA hypomethylation found in
many human tumours favours instability of particular chromo-
somes. Hypomethylation of satellite 2 DNA sequences located in
juxtacentromeric heterochromatin on chromosomes 1q and 16q
correlates with loss of these chromosome arms in ovarian carci-
noma and other tumours (Qu et al, 1999a,b; Saito et al, 2001). It is
thought that hypomethylation of the satellite DNA favours recom-
bination events thereby causing an increased propensity for chro-
mosomal breaks (Tuck-Muller et al, 2000). Chromosome 9q12
contains another major region of juxtacentromeric heterochro-
matin, mainly consisting of satellite 3 DNA and other repeats such
as MR9a. Since DNA methylation is diminished genome-wide in
most cases of TCC (Jürgens et al, 1996; Florl et al, 1999),
hypomethylation in the 9q12 region might account for the high
frequency of chromosome 9q loss and explain why loss of the
entire chromosome arm 9q predominates. This hypothesis predicts
that loss of chromosome 9q in TCC is related to the extent of DNA
hypomethylation. 
To address these hypotheses we present a study of LOH on
chromosomes 9p and 9q in – mostly advanced – TCC specimens,
including mutational analysis of the candidate tumour suppressor
gene DBCCRI and a correlation with DNA methylation levels. 
MATERIALS AND METHODS 
Patients and tissue samples 
TCC samples were obtained by cystectomy, nephrectomy, or
transurethral resection from 81 patients between 1994 and 1999.
Tumours and corresponding normal tissues were dissected after
surgery, frozen in liquid nitrogen, and stored at –80˚C. Blood
samples from tumour patients were routinely collected for DNA
extraction. Grading and staging were performed according to the
1997 UICC classification for bladder carcinoma. Among the 81
patients, 63 were male and 18 female. Ages ranged from 41 to 87
years with a mean age of 65.7 ± 9.1 years. In all, 5 tumours were
staged as pTa, 8 carcinomas as pT1, 24 as pT2, 33 as pT3, and 11
as pT4. Three tumours were graded as G1, 23 as G2, 55 as G3, and
4 as G4, respectively. The study was favourably reviewed by the
ethics committee of the Heinrich-Heine-University. 
DNA extraction 
High molecular weight genomic DNA was isolated from frozen
tissues and whole blood using the blood and cell culture DNA kit
(Qiagen, Hilden, Germany). 
LOH analysis 
Matched pairs of normal and tumour DNA samples were screened
for LOH at 9q at the 14 microsatellite loci D9S1862, D9S273,
D9S15, D9S153, D9S283, D9S196, D9S287, D9S180, D9S176,
D9S53, D9S1872, D9S63, D9S1847, and D9S158 (cf Figure 1)
using primer sequences obtained from the Genome DataBase.
Testing of markers was performed in duplex or triplex PCR
analyses repeated at least twice. Template DNA (100 ng) was
amplified in a total volume of 50 µ l containing 150 µ M of each
dNTP, 1.5 mM MgCl2, 10–100 pmol of each primer (forward
primers modified at the 5′ -end with IRD800), and 2 U of
DyNAzymeII Taq polymerase (Biozym, Göttingen, Germany).
Following initial denaturation at 95˚C for 5 min, 30–35 cycles of
30 s at 94˚C, 30 s at 55˚C or 60˚C, and 1 min at 72˚C were
performed. All reactions included a final elongation step at 72˚C for
10 min. PCR products were analysed on an automated infrared
DNA electrophoresis system (LI-COR dNA 4000/4200, MWG-
Biotech, Ebersberg, Germany). Following addition of 4 µ l of
loading buffer to the 1:10-diluted PCR product, the sample was
heated to 95˚C for 5 min and snap-cooled. From each mixture,
1.5 µ l per lane was loaded onto a 6% denaturing polyacrylamide
gel (SequaGel, National Diagnostics, Atlanta, Georgia) pre-run
for 30 min at 1000 V. Electrophoresis was carried out at a
constant voltage of 1000 V at 50˚C. The data are presented as an
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Figure 1 Microsatellites and candidate tumour suppressor genes on
chromosome 9. The order and approximate positions of microsatellites used
in the study (left column) and the position of selected candidate tumour
suppressor genes for TCC (right column) are indicated radioautograph-like image that is stored in TIF format using the
image manipulation subprogram of the LICOR Base ImagIR soft-
ware package. Band analysis was performed using OneDScan 1.2
software (MWG-Biotech). An allele was regarded as lost when the
intensity of the remaining signal was less than 60% of the signal
from the same allele in the matching control DNA of the same
patient, as previously described (Florl et al, 2000). 
Homozygous deletions were identified by analyses of D9S942
microsatellite signals in multiplex reactions and confirmed by
quantitative PCR of CDKN2A exons as described (Florl et al,
2000). 
Mutation analysis of DBCCRI
Ten pairs of primers designed to amplify the entire coding region
of DBCCRI from genomic DNA were used (Habuchi et al, 1998).
For exon 8 analysis, four pairs of primers were used to amplify the
coding region as overlapping fragments. Primers were synthesized
and labelled with FAM (sense primer) or TET (antisense) phos-
phoramidite dyes. PCR reactions were carried out under standard
conditions. Cycle times were as follows: 95˚C for 4 min, 5 cycles
of 95˚C for 60 s and 72˚C for 90 s followed by 25 cycles of 95˚C
for 60 s, 55˚C for 60 s and 72˚C for 90 s. Products were combined
with formamide and TAMRA-500 standards (PE Biosystems,
Warrington, UK), denatured at 95˚C for 2 min and snap-cooled in
iced water. Samples were loaded onto 36 cm well to read 6.5%
(49:1) acrylamide, 5% glycerol gels on an ABI 377 DNA
sequencer linked to an external circulating cooling water bath set
at 18˚C. Run conditions were set at 50 W power limiting and gels
run for up to 16 h. Data was collected using ABI Genescan 3.1
software and analysed using ABI Genotyper 2.5 software (PE
Biosystems). Products from exons 8C and 8D were 426 and 436
bp, respectively. These products were also assessed by denaturing
high performance liquid chromatography (DHPLC) using a
Transgenomic WAVE HPLC (Transgenomic™) and DNASep
column (Transgenomic™) as described (Kuklin et al, 1997).
Buffer A contained 0.1 M triethylammonium acetate (TEAA).
Buffer B contained 0.1 M TEAA and 25% acetonitrile. Analysis
was carried out at a flow rate of 0.9 ml per min and a buffer B
gradient increase of 2% per min for 4 min. Start and end concen-
trations of buffer B were determined empirically for each frag-
ment. Eluation of DNA from the column was detected by
absorbance at 260 nm. PCR fragments which showed abnormal
migration of elution profiles were re-amplified using the
corresponding non-labelled primer pair and sequenced (Big Dye
Terminator kit, PE Biosystems). 
Methylation analysis 
Genome-wide hypomethylation was analysed on Southern blots
using a LINE-1 probe as described (Jürgens et al, 1996). In normal
somatic tissues, LINE-1 sequences are almost completely methyl-
ated. Hypomethylation results in the appearance of lower size
bands (0.5 to 4 kb) after digestion with Hpa II. The data are
expressed as % hypomethylation, which is the intensity of these
bands after Hpa II compared to Msp I digestion. The value in
normal bladder tissue is 0.5–1%. Southern blot analysis was
employed as well to determine satellite methylation using the
pMR9a (Rocchi et al, 1991) probe kindly provided by Dr Rocchi,
Bari, Italy. 
RESULTS 
Eighty-one TCC specimens previously characterized for chromo-
some 9p loss (Florl et al, 2000) were further analysed for LOH
using microsatellite markers spaced across chromosome 9q
(Figure 1). Approximately one half of the tumours (41/81 = 51%)
showed LOH on 9q (Table 1). LOH at all markers investigated was
observed in 33 cases (41%), whereas eight showed partial losses
(cases a –h in Figure 2). In this group, the partial losses occurred in
three regions: the most centromeric region encompassed markers
9S1862 to 9S15, the second region centred around 9S176, and the
most telomeric region involved 9S1872 to 9S158 (Figure 2, right). 
In most cases (85%), LOH at all markers on 9q was accompa-
nied by LOH of markers around CDKN2A on 9p; only five TCC
with complete loss of 9q had retained all 9p markers and only two
had 9p LOH only. All but one specimen with homozygous deletion
in the CDKN2 locus showed LOH for all markers on chromo-
some 9q; in one exceptional case (designated h in Figure 2) only
the distal part of chromosome 9q was affected. This was one of
three specimens with partial losses on 9q also displaying alter-
ations on 9p. 
Three samples (c, g and h) had discrete deletions that included
the candidate tumour suppressor gene DBCCRI at 9q32–33 and
were therefore screened for mutations on the retained allele. No
tumour-specific sequence alterations were found. 
Since apparent retention of homozygosity within a region of
LOH is a useful indicator for homozygous deletions in tumour
Chromosome 9 destabilization in TCC  1889
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Table 1 LOH on chromosome 9q in relation to clinical and molecular parameters 
9q retention (%) 9q partial loss (%) 9q complete loss (%) Total (%) 
pTa + pT1 6 (46.2) 1 (7.7) 6 (46.2) 13 (100) 
pT2 – pT4 34 (50.0) 7 (10.3) 27 (39.7) 68 (100) 
G1 2 (100) 0 (0) 0 (0) 2 (100) 
G2 9 (39.1) 3 (13.0) 11 (47.8) 23 (100) 
G3 29 (51.8) 5 (8.9) 22 (39.3) 56 (100) 
N0 and M0 28 (45.9) 8 (13.1) 25 (41.0) 61 (100) 
N + or M + 12 (60.0) 0 (0) 8 (40.0) 20 (100) 
9p intact 38 (79.2) 5 (10.4) 5 (10.4) 48 (100) 
9p abnormal 2 (6.1) 3 (9.1) 28 (84.8) 33 (100) 
CDKN2A HD 0 (0) 1 (5.6) 17 (94.4) 18 (100) 
Recurrence with progression 4 (50.0) 0 (0) 4 (50.0) 8 (100) 
Recurrence without progression 4 (50.0) 0 (0) 4 (50.0) 8 (100) 
Total 40 (49.4) 8 (9.9) 33 (40.7) 81 (100) tissue samples containing contaminating normal tissue (cf Florl
et al, 2000), all such instances were carefully rechecked in
repeated multiplex analyses. However, no homozygous deletion
on chromosome 9q could be confirmed, even though at least 18
(22%) of the specimens in the series contain homozygous dele-
tions in the CDKN2A locus on chromosome 9p (Table 1, cf Florl
et al, 2000). 
The presence of chromosome 9q alterations was neither
related to tumour stage nor to tumour grade nor to the presence of
metastases (Table 1). On the contrary, for every stage and grade
the proportion of tumours with 9q LOH ranged between 40% and
56% of the total. Partial loss on 9q seemed to occur more often in
more advanced tumours, but due to its low frequency, this relation-
ship could not be statistically evaluated. All but one of the tumours
with homozygous deletions at CDKN2A had LOH across the entire
9q arm (Table 1). 
A detailed medical history was available for 73 patients. Sixteen
tumour specimens in this study were from recurrences with initial
papillary tumours (pTa or pT1). Half of these had progressed in
stage or grade. LOH on 9q was found in four specimens each from
the progressive group and from the non-progressive group with
four specimens each retaining all tested markers on 9q. No case of
partial loss was found among these 16 specimens. 
Most of the tumour specimens exhibited often very pronounced
DNA hypomethylation (Figure 3), as measured by loss of methylated
sites in LINE-1 retrotransposons distributed throughout the
genome. DNA hypomethylation was observed in specimens with
9q retention as well as 9q loss, but was on average much more
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Figure 2 Partial LOH on chromosome 9q in TCC. The figure shows a compilation of partial deletions on chromosome 9q mapped in the present study (cases
a–h) and published in the literature (A: Simoneau et al, 1996, B: Ohgaki et al, 1999, C: van Tilborg et al, 1999, D: Habuchi et al, 1995, E: Habuchi et al, 1997, 
F: Nishiyama et al, 1999, G: Hornigold et al, 1995). Microsatellite markers, their order and approximate position are indicated. Squares black: LOH;
white: retention, dotted: not informative, triangle: homozygous deletion. DBCCR1 is located near S195 pronounced in the latter group (mean ± S.D.: 27 ± 19% vs 10 ±
10%). This difference was highly significant (P < 0.00001 in a
Wilcoxon sum analysis). In the eight tumours with partial 9q loss,
DNA hypomethylation ranged from 5% to 57% with a mean ±
S.D. of 20 ± 16% and was thus still more pronounced than in the
specimens without alterations of chromosome 9. 
To obtain a more specific indication of the methylation status of
repetitive sequences in the 9q juxtacentromeric region, 11 bladder
cancer tissues previously characterised for LINE methylation were
randomly selected and investigated by Southern hybridization
with a chromosome 9 specific satellite probe (pMR9a) following
DNA digestion with either of the restriction enzyme isoschizomers
Hpa II and Msp I that are sensitive and non-sensitive to DNA
methylation, respectively. As expected, the satellite sequence was
strongly methylated in normal bladder tissue, as evidenced by a
lack of lower size bands after Hpa II digestion as compared to Msp
I digestion (Figure 4). In contrast, methylation of the satellite
sequence was decreased in 7 of the 11 TCC tissues indicating that
DNA hypomethylation also extends to the heterochromatic
sequences (Figure 4). 
DISCUSSION 
The results of the LOH analyses presented here agree with many
other published studies in that a high percentage of TCC show
losses across the entire long arm of chromosome 9 (in the present
study 33/81 = 41%). Some of these studies have hinted at the
possibility that loss of 9q might be an early step in TCC develop-
ment and might be more frequent in papillary tumours. If so, losses
of 9q in advanced tumours, which comprise the majority of cases
in this study, ought to be often associated with a previous history
of papillary tumours. Our data on patient history do not fit with
this assumption, since recurrent TCC with a papillary tumour
history displayed 9q LOH and retention at the same frequency.
Likewise, the data contradict the assumption that LOH on 9q
Chromosome 9 destabilization in TCC  1891
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Figure 3 9q loss and DNA hypomethylation. The extent of genome-wide
DNA hypomethylation as measured by decreased methylation of LINE-1
retrotransposon sequences is indicated for each TCC specimen. The nearly
complete methylation of LINE-1 sequences in normal tissue is set at 0%.
From left to right the columns show TCCs with (1) LOH on neither 9p nor 9q,
(2) LOH at all studied markers on 9q, (3) LOH at all markers on 9q and/or
markers on 9p (one case more than (2)), (4) LOH at any marker on 9q (eight
more cases than (2)). Horizontal bars indicate median values 
HMHMHMHMHMHMHM
C9 C8 C13 C4 A6 A11 BN
Bladder tumour
0.34 kb
1.3 kb
2.0 kb
2.7 kb
3.5 kb
Figure 4 Southern blot analysis of satellite sequence methylation. DNA
from TCC specimens and from normal bladder was digested with Hpa II (H)
or Msp I (M), blotted and hybridized with the pMR9a satellite probe.
Approximate band sizes are indicated on the right hand side (note that they
represent multiples of the 0.34 kb basic repeat). Because the enzyme
recognition sequence is lacking in many repeats, most of the hybridization
signal is present in the high molecular weight bands. Additional bands in the
Hpa II lane compared to the Msp I lane indicate hypomethylation, most
pronounced in specimen C4. The decreased intensity of the 3.5 kb band in
the Msp I lane in the same specimen is due to a known polymorphism
(Rocchi et al, 1991) occurs essentially as a consequence of selection for CDKN2A
inactivation. This hypothesis would predict that in advanced
tumours 9p loss would be more frequent than 9q loss, whereas in
our series localized LOH around CDKN2A was rather less
frequent than LOH on 9q. Five cases showed LOH at all tested
markers on 9q without alterations on 9p as compared to only two
case of isolated 9p LOH. In addition, no changes around CDKN2
were found in many cases with partial 9q losses. 
While these findings are compatible with the idea that chromo-
some 9q carries one or several tumour suppressor genes
contributing to TCC development, the identification of the rele-
vant gene(s) has proved to be extremely difficult. In the present
study, as in most others, only few tumours showed partial losses on
9q (8/81 = 10%). In the standard interpretation, the data (cf. Figure 2)
would be taken to indicate tumour suppressor genes located in
9q12 (near 9S273), 9q22.3 (near S176), and more distally in
9q33–9q34. Although these locations do roughly correspond to
those identified by other groups (see Figure 2), this interpretation
should be applied with great caution. A detailed compilation of the
published cases with partial 9q LOH (see Figure 2) rather suggests
that partial losses can occur anywhere on chromosome 9q. This
argument is strengthened by studies (Simoneau et al, 2000; van
Tilborg et al, 2000) not included in the compilation that have
reported a higher frequency of smaller deletions in up to five
different regions of chromosome 9q, particularly in early stage
tumours. 
Since even moderately advanced stage TCC carry many
different chromosomal alterations, it cannot be assumed that each
one observed is functionally important. Rather, some low
frequency changes may be functionally irrelevant but are carried
along during expansion of the particular cell clone in which the
events crucial for tumorigenesis and progression occurred. LOH
and cytogenetic studies (Knowles et al, 1994; Kallioniemi et al
1995; Bruch et al, 1998; Richter et al, 1999; Fadl-Elmula et al,
2000) have shown that in TCC almost every chromosome is
affected at a rate similar to that found for the frequency of partial
chromosome 9q losses in this study (10%) and others. Moreover,
in this study the partial losses tended to occur in advanced cancers.
Taken together, there is no compelling reason to assume that indi-
vidual cases of partial losses on chromosome 9q indicate the pres-
ence of a tumour suppressor gene target. Nevertheless, generalized
chromosomal instability cannot explain why specifically loss of an
entire chromosome 9q occurs so consistently in TCC. 
As pointed out above, a consistent genetic alteration in a tumour
can be a consequence of the particular mechanism driving
genomic instability or of functional selection, or both. It seems
likely that the preferential loss of chromosome 9q in TCC has a
mechanistic cause. Chromosome 9, like chromosomes 1 and 16,
contains an extended heterochromatic region juxtaposed to the
centromere, composed mostly of satellite DNA. On chromosome
9, satellite 3 with sequences like pMR9a constitutes the bulk,
whereas satellite 2 predominates on chromosomes 1 and 16. In the
chromosome instability syndrome ICF, these satellites remain essen-
tially unmethylated due to mutation of the DNA methyltransferase
3B. This causes unfolding of the juxtacentromeric heterochro-
matin and formation of unusual radial chromosomes from which
chromosome arms involved, viz. 1p, 1q, 16p, or 16q, become lost
(Xu et al, 1999). The same or a similar mechanism accounts prob-
ably for the loss of 1q or 16q in tumours with hypomethylated
DNA (Tuck-Muller et al, 2000). Since our data demonstrate that
9q loss correlates with genome-wide hypomethylation (Figure 3),
hypomethylation also affects 9q12 sequences (Figure 4) and LOH
extends far into 9q12 (Figure 2 and data not shown), a related
mechanism may also be involved in 9q loss in TCC. Radials
formed from two chromosomes 9 could lose either 9q or 9p or
both, the latter accounting for monosomy. Interestingly, one study
(van Tilborg et al, 1998) has suggested that many cases of total
chromosome 9 loss in TCC do not exhibit true monosomy, but
rather losses of 9p from one chromosome and 9q from the other,
which would be explained by the mechanism suggested here. 
While instability of juxtacentromeric heterochromatin caused
by DNA hypomethylation would explain the frequency of 9q loss
and the predominance of loss of the entire arm, it does not account
for the preferential loss of chromosome 9q as compared to 1q or
16q. Since, moreover, our data argue that 9p loss does not drive 9q
loss, there is a strong argument for a tumour suppressor gene on
9q. However, the rarity of second hits by deletion on the remaining
chromosome arm apparent from this and other studies suggests
that this tumour suppressor may not conform to the standard two-
hit-hypothesis. Since haploinsufficiency is one possible explana-
tion, it will be important to determine the effect of loss of a single
copy of candidate genes like DBCCR1, PTCH, or TGFBRI, singly
or combined, on urothelial growth and differentiation. 
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